30 Gy reduced to 20 Gy
Diffuse large B-cell lymphoma
Accrual complete
Study of Dose-Reduced Consolidation Radiation Therapy in Patients with Diffuse Large B-cell Lymphoma
This phase II study will evaluate whether a reduction in the dose of consolidation RT in patients who achieve a negative post-chemotherapy PET-CT scan following 3 to 6 cycles of chemoimmunotherapy, will be associated with a low risk of in-field failure. The goal of this approach is to maintain excellent control rates while minimizing the risk of acute and late toxicity. The hypothesis is that after more effective systemic therapy (employing rituximab), and confirmation of optimal response to chemotherapy (negative post-chemotherapy PET-CT), the RT dose can be safely reduced from 30 Gy to 20 Gy while maintaining high rates of local control.
- Principal Investigators
- Dr Chris Kelsey (Duke)
- Participating Institutions
- Duke, MD Anderson Cancer Center, Yonsei Cancer Center, Juntendo University, SingHealth, University of Rochester, Mayo Clinic, Dana-Farber/Brigham and Women's
241 patients enrolled; accrual completed in 2023. Long-term results of the original Duke phase 2 study were published in 2025.
Download the protocol (PDF)NCT03681535 on ClinicalTrials.govLong-term update of the Duke phase 2 study (IJROBP 2025)
